Journals / ANKEM Dergisi / 2008 / Cilt: 22 - Sayı: 3

Association of anti-CD20 antibody-rituximab and infection: A case report

Anti-CD20 antikor-rituksimab ve infeksiyon ilişkisi: Bir olgu nedeniyle

Pages
156–159
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper we aimed to evaluate the relationship between rituximab treatments and infections, and attract attention to the issue with a panophtalmitis case with lymphoma who was on CHOP-R treatment and ended up with death.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In recent years, serious viral, mycobacterial and fungal infection cases which developed after anti-CD20 antibodies (rituximab) have been published.
📊
Key Findings & Data:Upto now there was no panophtalmitis case associated with rituximab.
💡
Conclusion & Impact:In this paper we aimed to evaluate the relationship between rituximab treatments and infections, and attract attention to the issue with a panophtalmitis case with lymphoma who was on CHOP-R treatment and ended up with death.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Panoftalmit · Antijenler · CD20

Abstract

In recent years, serious viral, mycobacterial and fungal infection cases which developed after anti-CD20 antibodies (rituximab) have been published. Upto now there was no panophtalmitis case associated with rituximab. In this paper we aimed to evaluate the relationship between rituximab treatments and infections, and attract attention to the issue with a panophtalmitis case with lymphoma who was on CHOP-R treatment and ended up with death.

Özet

Son yıllarda literatürde anti-CD20 antikoru (rituksimab) tedavisi sonrası gelişen ciddi viral, mikobakteriyel ve fungal infeksiyonlar bildirilmektedir. Şimdiye kadar rituksimab ilişkili panoftalmit bildirilmemiş olup, CHOP-R tedavisi alan lenfomalı bir olguda ölümle sonlanan panoftalmit tablosu nedeni ile konuya dikkat çekilmesi ve rituksimab tedavileri ile infeksiyon ilişkisinin değerlendirilmesi amaçlanmıştır.

🔖

Cite This Article

KURTARAN, B., PAYDAŞ, S., CANDEVİR, A., YAVUZ, S., İNAL, A. S. (2008). Association of anti-CD20 antibody-rituximab and infection: A case report. ANKEM Dergisi, Cilt: 22 - Sayı: 3, 156–159. https://ajindex.com/articles/193172

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Aksoy S, Harputluoglu H, Kilickap S et al: Rituximab- related viral infections in lymphoma patients, Leuk Lymphoma 2007;48(7):1307-12
  2. Archimbaud C, Bailly JL, Chambon M, Tournilhac O, Travade Peique-Lafeuille HP: Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in 2000, J Clin Microbiol 2003;41(10):4605-10
  3. Cabanillas F, Liboy I, Pavia O, Rivera E: High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication, Ann Oncol 2006;17(9):1424-7
  4. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D: Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008;67(3):283-7
  5. Cattaneo C, Spedini P, Casari S et al: Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments, Leuk Lymphoma 2006;47(6):1013-7
  6. Coiffier B, Lepage E, Briere J et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med 2002;346(4):235-42
  7. Coiffier B, Salles G, Pfreundschuh M, Loeffler M: Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma, Blood 2004;104(5):1584-5
  8. Czuczman MS, Koryzna A, Mohr A et al: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma, J Clin Oncol 2005;23(4):694-704
  9. Feugier P, Van Hoof A, Sebban C et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte, J Clin Oncol 2005;23(18):4117-26
  10. Habermann TM, Weller EA, Morrison VA et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma, J Clin Oncol 2006;24(19):3121-7
  11. Hiddemann W, Kneba M, Dreyling M et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advancedstage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, Blood 2005;106(12):3725-32
  12. Lenz G, Dreyling M, Hoster E et al: Immunochem